Haleon (HLN) Return on Sales (2021 - 2025)

Haleon's (HLN) quarterly Return on Sales came in at 0.0% in Q4 2025, down 29.96% on a QoQ basis from 0.0% in Q4 2023.

Haleon (HLN) Return on Sales (2021 - 2025) Analysis & Trends

Haleon (HLN) has 4 years of Return on Sales data on file, last reported at 0.0% in Q4 2025.

Quarterly Return on Sales changed N/A year-over-year to 0.0% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.0% (changed N/A YoY) and the FY2025 annual result came in at 0.0%, changed 0.0% from the prior year.
Return on Sales slipped to 0.0% in Q4 2025, from 0.0% in the prior quarter.
In the past five years, Return on Sales ranged from a high of 0.01% in Q4 2022 to a low of 0.0% in Q4 2025.
A 4-year average of 0.0% and a median of 0.0% in 2023 frame the typical range for Return on Sales.
The widest YoY moves for Return on Sales: up 0 bps in 2022, down 0 bps in 2022.
Tracing HLN's Return on Sales over 4 years: stood at 0.0% in 2021, then jumped by 207 bps to 0.01% in 2022, then plunged by 69 bps to 0.0% in 2023, then dropped by 30 bps to 0.0% in 2025.
The last three Return on Sales figures came in at 0.0% (Q4 2025), 0.0% (Q4 2023), and 0.0% (Q2 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Haleon	44.07 Bn	43.10 Bn	-	-
2	Teva Pharmaceutical Industries	43.42 Bn	39.76 Bn	2.15 Bn	0.00%
3	Zoetis	31.86 Bn	30.18 Bn	1.05 Bn	0.00%
4	Takeda Pharmaceutical	28.77 Bn	22.98 Bn	5.10 Bn	0.00%
5	United Therapeutics	22.29 Bn	19.63 Bn	683.80 Mn	0.00%
6	Viatris	18.78 Bn	17.89 Bn	1.46 Bn	0.00%
7	Neurocrine Biosciences	15.66 Bn	15.27 Bn	935.80 Mn	0.00%
8	Elanco Animal Health	11.91 Bn	11.38 Bn	798.00 Mn	0.00%
9	Dr Reddys Laboratories	10.16 Bn	10.00 Bn	-	-
10	Alkermes	8.20 Bn	7.55 Bn	397.90 Mn	0.00%

Download Data